Skip to main content
OpenTrials
Completed

NCT Number: NCT01300819

Placebo-controlled Study in Patients With Parkinson's Disease to Evaluate the Effect of Rotigotine on Non-motor Symptoms

The primary objective of this study was to demonstrate that Rotigotine improves non-motor symptoms compared to Placebo in subjects with Parkinson's Disease.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

IDIOPATHIC PARKINSON'S DISEASE Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Movement Disorders Nervous System Diseases Neurodegenerative Diseases Parkinson Disease Parkinsonian Disorders Synucleinopathies

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

101, Feldbach, Austria

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject is male or female, ≥18 years of age
  • Subject has idiopathic Parkinson's disease with at least 2 of the following cardinal signs being present: bradykinesia, resting tremor, rigidity or postural instability, and without any other known or suspected cause of Parkinsonism
  • Subject has a Hoehn and Yahr stage score ≤4
  • Subject has a total Non-Motor Symptoms Scale (NMSS) score ≥40
  • If the subject is taking levodopa (L-DOPA), he/she must be on a stable dose of L-DOPA (in combination with benserazide or carbidopa) for at least 28 days prior to the Baseline Visit
  • If the subject is receiving anticholinergics, monoamine oxidase (MAO) B inhibitors, or amantadine, he/she must have been on a stable dose for at least 28 days prior to the Baseline Visit and must be maintained on that dose for the duration of the study

Exclusion criteria

  • Subject discontinued from previous therapy with a dopamine agonist after an adequate length of treatment, at an adequate dose, due to lack of efficacy as assessed by the investigator
  • Subject is receiving therapy with 1 of the following drugs, either concurrently or within 28 days prior to the Baseline Visit: alpha-methyl dopa, metoclopramide, reserpine, neuroleptics (except specific atypical neuroleptics: olanzapine, ziprasidone, aripiprazole, clozapine, and quetiapine), monoamine oxidase-A (MAO-A) inhibitors, methylphenidate, amphetamine, or other dopamine agonists (DAs)
  • Subject is receiving central nervous system (CNS) therapy (eg, sedatives, hypnotics, selective serotonin reuptake inhibitors [SSRIs], anxiolytics, or other sleep-modifying medication) unless dose has been stable daily for at least 28 days prior to the Baseline Visit and is likely to remain stable for the duration of the study
  • Subject has evidence of an impulse control disorder according to the modified Minnesota Impulsive Disorders Interview at the Screening Visit (Visit 1), confirmed by a positive structured clinical interview

Treatment and study plan

Placebo

Other

Placebo patches of 2, 4, 6 & 8 mg / 24 hours Daily application of Placebo patches starting at 2 mg / 24 hours (early Parkinson's Disease (PD) patients) or 4 mg / 24 hours (advanced PD patients). Dose was up-titrated in weekly increments of 2 mg / 24 hours until optimal or maximal dose was reached. Maximal dose was 8 mg / 24 hours for early PD patients and 16 mg / 24 hours for advanced PD patients.

Optimal or maximal dose was maintained for 12 weeks followed by a de-escalation by 2 mg / 24 hours every other day.

Rotigotine

Drug

Rotigotine patches of 2, 4, 6, and 8 mg / 24 hours

Once daily application of Rotigotine patches starting at 2 mg / 24 hours (early Parkinson's Disease (PD) patients) or 4 mg / 24 hours (advanced PD patients). Dose was up-titrated in weekly increments of 2 mg / 24 hours until optimal or maximal dose was reached. Maximal dose is 8 mg / 24 hours for early PD patients and 16 mg / 24 hours for advanced PD patients.

Optimal or maximal dose was maintained for 12 weeks followed by a de-escalation by 2 mg / 24 hours every other day.

Other names: Neupro®

Primary outcomes

  1. Change From Baseline to the End of Maintenance in Total Nonmotor Symptoms Scale (NMSS) Score

    Time frame: From Baseline (Day 1) to end of 12-week Maintenance (Day 84)

    The Nonmotor Symptoms Scale (NMSS) is a validated tool for rating frequency and severity of nonmotor symptoms in Parkinson's Disease (PD). The severity and frequency of the subject's nonmotor symptoms is assessed by the investigator in the following 9 domain categories: cardiovascular, including falls; sleep/fatigue; mood/cognition; perceptual problems/hallucinations; attention/memory; gastrointestinal tract; urinary; sexual function; miscellaneous. Severity and frequency are rated using a 4-point scale ranging from 0 (none) to 3 (severe; major source of distress or disturbance to subject) for severity and from 1 (rarely) to 4 (very frequent [daily or all the time]) for frequency. The total NMSS score ranges from 0 to 350. A negative change from Baseline to end of Maintenance indicates an improvement in NMSS.

Secondary outcomes

  1. Change From Baseline to the End of Maintenance in Total Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score

    Time frame: From Baseline (Day 1) to end of 12-week Maintenance (Day 84)

    The Unified Parkinson's Disease Rating Scale (UPDRS) Part III is a scale for the assessment of function in Parkinson's Disease. UPDRS Part III measures Motor Function. It consists of 14 items with 27 questions, each ranging from 0 to 4. The sum score for the UPDRS Part III ranges from 0 to 108. A higher score indicates greater disability. A negative change from Baseline to end of Maintenance score indicates improvement.

  2. Change From Baseline to the End of Maintenance in Health-related Quality of Life (HRQL) Measured by a 39-item Parkinson's Disease Questionnaire (PDQ-39)

    Time frame: From Baseline (Day 1) to end of 12-week Maintenance (Day 84)

    Parkinson's Disease Questionnaire - 39 (PDQ-39) is a self-administered questionnaire. It comprises of 39 questions, relating to eight key areas of health and daily activities, including both Motor and Non-motor symptoms. It is scored on a scale of zero to 100, with lower scores indicating better health and high scores more severe symptoms in change from Baseline to end of Maintenance.

  3. Change From Baseline to the End of Maintenance in the Nonmotor Symptoms Scale Score: Subdomain Cardiovascular

    Time frame: From Baseline (Day 1) to end of 12-week Maintenance (Day 84)

    The Nonmotor Symptoms Scale (NMSS) is a validated tool for rating frequency and severity of nonmotor symptoms in Parkinson's Disease (PD). The severity and frequency of the subject's nonmotor symptoms is assessed by the investigator in 9 different domains. Severity (ranges: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe) and frequency (ranges: 1 = Rarely (<1/wk), 2 = Often (1/wk), 3 = Frequent (several times per week), 4 = Very Frequent (daily or all the time) are rated using a 4-point scale.

    The final score is derived from multiplying the severity score and the frequency score.

    A negative change from Baseline to end of Maintenance indicates an improvement in NMSS.

    The possible min/max final scores per subdomain are calculated as follows:

    Range of final score per subdomain: 0 - 12 per question multiplied by the number of questions per subdomain:

    Subdomain Cardiovascular (2 questions): range 0 - 24

  4. Change From Baseline to the End of Maintenance in the Nonmotor Symptoms Scale Score: Subdomain Sleep/Fatigue

    Time frame: From Baseline (Day 1) to end of 12-week Maintenance (Day 84)

    The Nonmotor Symptoms Scale (NMSS) is a validated tool for rating frequency and severity of nonmotor symptoms in Parkinson's Disease (PD). The severity and frequency of the subject's nonmotor symptoms is assessed by the investigator in 9 different domains. Severity (ranges: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe) and frequency (ranges: 1 = Rarely (<1/wk), 2 = Often (1/wk), 3 = Frequent (several times per week), 4 = Very Frequent (daily or all the time) are rated using a 4-point scale.

    The final score is derived from multiplying the severity score and the frequency score.

    A negative change from Baseline to end of Maintenance indicates an improvement in NMSS.

    The possible min/max final scores per subdomain are calculated as follows:

    Range of final score per subdomain: 0 - 12 per question multiplied by the number of questions per subdomain:

    Subdomain Sleep/Fatigue (4 questions): range 0-48

  5. Change From Baseline to the End of Maintenance in the Nonmotor Symptoms Scale Score: Subdomain Mood/Cognition

    Time frame: From Baseline (Day 1) to end of 12-week Maintenance (Day 84)

    The Nonmotor Symptoms Scale (NMSS) is a validated tool for rating frequency and severity of nonmotor symptoms in Parkinson's Disease (PD). The severity and frequency of the subject's nonmotor symptoms is assessed by the investigator in 9 different domains. Severity (ranges: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe) and frequency (ranges: 1 = Rarely (<1/wk), 2 = Often (1/wk), 3 = Frequent (several times per week), 4 = Very Frequent (daily or all the time) are rated using a 4-point scale.

    The final score is derived from multiplying the severity score and the frequency score.

    A negative change from Baseline to end of Maintenance indicates an improvement in NMSS.

    The possible min/max final scores per subdomain are calculated as follows:

    Range of final score per subdomain: 0 - 12 per question multiplied by the number of questions per subdomain:

    Subdomain Mood/Cognition (6 questions): range 0 - 72

  6. Change From Baseline to the End of Maintenance in the Nonmotor Symptoms Scale Score: Subdomain Perception/Hallucinations

    Time frame: From Baseline (Day 1) to end of 12-week Maintenance (Day 84)

    The Nonmotor Symptoms Scale (NMSS) is a validated tool for rating frequency and severity of nonmotor symptoms in Parkinson's Disease (PD). The severity and frequency of the subject's nonmotor symptoms is assessed by the investigator in 9 different domains. Severity (ranges: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe) and frequency (ranges: 1 = Rarely (<1/wk), 2 = Often (1/wk), 3 = Frequent (several times per week), 4 = Very Frequent (daily or all the time) are rated using a 4-point scale.

    The final score is derived from multiplying the severity score and the frequency score.

    A negative change from Baseline to end of Maintenance indicates an improvement in NMSS.

    The possible min/max final scores per subdomain are calculated as follows:

    Range of final score per subdomain: 0 - 12 per question multiplied by the number of questions per subdomain:

    Subdomain Perception/Hallucinations (3 questions): range 0 - 36

  7. Change From Baseline to the End of Maintenance in the Nonmotor Symptoms Scale Score: Subdomain Attention/Memory,

    Time frame: From Baseline (Day 1) to end of 12-week Maintenance (Day 84)

    The Nonmotor Symptoms Scale (NMSS) is a validated tool for rating frequency and severity of nonmotor symptoms in Parkinson's Disease (PD). The severity and frequency of the subject's nonmotor symptoms is assessed by the investigator in 9 different domains. Severity (ranges: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe) and frequency (ranges: 1 = Rarely (<1/wk), 2 = Often (1/wk), 3 = Frequent (several times per week), 4 = Very Frequent (daily or all the time) are rated using a 4-point scale.

    The final score is derived from multiplying the severity score and the frequency score.

    A negative change from Baseline to end of Maintenance indicates an improvement in NMSS.

    The possible min/max final scores per subdomain are calculated as follows:

    Range of final score per subdomain: 0 - 12 per question multiplied by the number of questions per subdomain:

    Subdomain Attention/Memory (3 questions): range 0 - 36

  8. Change From Baseline to the End of Maintenance in the Nonmotor Symptoms Scale Score: Subdomain Gastrointestinal Tract

    Time frame: From Baseline (Day 1) to end of 12-week Maintenance (Day 84)

    The Nonmotor Symptoms Scale (NMSS) is a validated tool for rating frequency and severity of nonmotor symptoms in Parkinson's Disease (PD). The severity and frequency of the subject's nonmotor symptoms is assessed by the investigator in 9 different domains. Severity (ranges: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe) and frequency (ranges: 1 = Rarely (<1/wk), 2 = Often (1/wk), 3 = Frequent (several times per week), 4 = Very Frequent (daily or all the time) are rated using a 4-point scale.

    The final score is derived from multiplying the severity score and the frequency score.

    A negative change from Baseline to end of Maintenance indicates an improvement in NMSS.

    The possible min/max final scores per subdomain are calculated as follows:

    Range of final score per subdomain: 0 - 12 per question multiplied by the number of questions per subdomain:

    Subdomain Gastrointestinal tract (3 questions): range 0 - 36

  9. Change From Baseline to the End of Maintenance in the Nonmotor Symptoms Scale Score: Subdomain Urinary

    Time frame: From Baseline (Day 1) to end of 12-week Maintenance (Day 84)

    The Nonmotor Symptoms Scale (NMSS) is a validated tool for rating frequency and severity of nonmotor symptoms in Parkinson's Disease (PD). The severity and frequency of the subject's nonmotor symptoms is assessed by the investigator in 9 different domains. Severity (ranges: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe) and frequency (ranges: 1 = Rarely (<1/wk), 2 = Often (1/wk), 3 = Frequent (several times per week), 4 = Very Frequent (daily or all the time) are rated using a 4-point scale.

    The final score is derived from multiplying the severity score and the frequency score.

    A negative change from Baseline to end of Maintenance indicates an improvement in NMSS.

    The possible min/max final scores per subdomain are calculated as follows:

    Range of final score per subdomain: 0 - 12 per question multiplied by the number of questions per subdomain:

    Subdomain Urinary (3 questions): range 0 - 36

  10. Change From Baseline to the End of Maintenance in the Nonmotor Symptoms Scale Score: Subdomain Sexual Function

    Time frame: From Baseline (Day 1) to end of 12-week Maintenance (Day 84)

    The Nonmotor Symptoms Scale (NMSS) is a validated tool for rating frequency and severity of nonmotor symptoms in Parkinson's Disease (PD). The severity and frequency of the subject's nonmotor symptoms is assessed by the investigator in 9 different domains. Severity (ranges: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe) and frequency (ranges: 1 = Rarely (<1/wk), 2 = Often (1/wk), 3 = Frequent (several times per week), 4 = Very Frequent (daily or all the time) are rated using a 4-point scale.

    The final score is derived from multiplying the severity score and the frequency score.

    A negative change from Baseline to end of Maintenance indicates an improvement in NMSS.

    The possible min/max final scores per subdomain are calculated as follows:

    Range of final score per subdomain: 0 - 12 per question multiplied by the number of questions per subdomain:

    Subdomain Sexual function (2 questions): range 0 - 24

  11. Change From Baseline to the End of Maintenance in the Nonmotor Symptoms Scale Score: Subdomain Miscellaneous

    Time frame: From Baseline (Day 1) to end of 12-week Maintenance (Day 84)

    The Nonmotor Symptoms Scale (NMSS) is a validated tool for rating frequency and severity of nonmotor symptoms in Parkinson's Disease (PD). The severity and frequency of the subject's nonmotor symptoms is assessed by the investigator in 9 different domains. Severity (ranges: 0 = None, 1 = Mild, 2 = Moderate, 3 = Severe) and frequency (ranges: 1 = Rarely (<1/wk), 2 = Often (1/wk), 3 = Frequent (several times per week), 4 = Very Frequent (daily or all the time) are rated using a 4-point scale.

    The final score is derived from multiplying the severity score and the frequency score.

    A negative change from Baseline to end of Maintenance indicates an improvement in NMSS.

    The possible min/max final scores per subdomain are calculated as follows:

    Range of final score per subdomain: 0 - 12 per question multiplied by the number of questions per subdomain:

    Subdomain Miscellaneous (4 questions): range 0 - 48

Sponsors and collaborators

Lead sponsor

UCB Pharma

Industry

Registry information

Official study title

Multicenter, Double-blind, Placebo-controlled, Parallel-group, Phase IV Study to Assess the Effect of Rotigotine on Non-motor Symptoms in Patients With Idiopathic Parkinson's Disease

Important dates

Study start
2011
Primary completion
2012
Study completion
2012
First posted
Feb 23, 2011
Registry last updated
May 9, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.